Oxaliplatin: in operable colorectal cancer

Area of Science:

• Oncology
• Clinical Trials
• Cancer Therapeutics

Background:

• Oxaliplatin is approved for metastatic colorectal cancer.
• Its efficacy in advanced disease prompted investigation in operable settings.
• Adjuvant and neoadjuvant roles are being explored.

Purpose of the Study:

• To evaluate the efficacy of adding oxaliplatin to adjuvant chemotherapy for stage II/III colon cancer.
• To assess the impact of oxaliplatin on disease recurrence and survival.
• To explore the potential of oxaliplatin in neoadjuvant treatment for rectal cancer.

Main Methods:

• The MOSAIC trial involved 2246 patients with stage II or III colon cancer.
• Patients received either fluorouracil/folinic acid or the FOLFOX4 regimen (oxaliplatin plus fluorouracil/folinic acid).
• Phase I/II studies investigated preoperative oxaliplatin-based radiochemotherapy for rectal cancer.

Main Results:

• The FOLFOX4 regimen resulted in significantly greater 3-year disease-free survival (78% vs 73%; p = 0.002).
• FOLFOX4 demonstrated a 23% reduction in the risk of disease recurrence post-surgery.
• Neoadjuvant oxaliplatin showed potential for disease downstaging and sphincter preservation in rectal cancer.
• Oxaliplatin was generally well-tolerated, with manageable neurotoxicity and myelotoxicity.

Conclusions:

• Adding oxaliplatin to adjuvant fluoropyrimidine therapy (FOLFOX4) significantly improves disease-free survival and reduces recurrence risk in stage II/III colon cancer.
• Oxaliplatin shows promise as part of neoadjuvant treatment for locally advanced rectal cancer.
• The FOLFOX4 regimen is a viable and generally well-tolerated option for adjuvant colon cancer treatment.